Literature DB >> 6982246

Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative.

C Damais, G Riveau, M Parant, J Gerota, L Chedid.   

Abstract

N-acetylmuramyl-L-alanyl-D-isoglutamine or MDP is a synthetic immunoadjuvant capable of inducing a febrile response in the rabbit and of eliciting production of endogenous pyrogen (EP) in vivo and in vitro. It was also shown to stimulate in vitro lymphocyte activating factor (LAF) release. After conjugation to a synthetic carrier, the pyrogenic effect of MDP is strongly enhanced. Recently, adjuvant active derivatives of MDP devoid of pyrogenicity such as MDP(Gln)-OnBu (AcMur-L-Ala-D-Gln-alpha-nbutyl ester) have become available. In the present study, their stimulating properties on rabbit peritoneal exudate cells or human peripheral blood mononuclear cells were simultaneously evaluated by testing lymphocyte activating property and pyrogenic effect of the culture supernatant. In both types of cell cultures, whereas MDP elicited dual effects, the nonpyrogenic analog MDP(Gln)-OnBu produced LAF without detectable pyrogenicity even when a very sensitive assay (intracerebroventricular administration) was used. In contrast, conjugated MDP was capable of inducing the production of endogenous pyrogen in rabbit cell cultures with no or little LAF release. These results argue against the possibility that a single factor is responsible for both LAF and EP activities.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982246     DOI: 10.1016/0192-0561(82)90020-0

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  26 in total

1.  Immunomodulatory and therapeutic properties of FK-565 in mice.

Authors:  J E Talmadge; B Lenz; M Schneider; H Phillips; C Long
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodium.

Authors:  D Archambault; G Morin
Journal:  Can Vet J       Date:  1988-01       Impact factor: 1.008

3.  Enhanced oxidative burst without interleukin 1 production by normal human polymorphonuclear leukocytes primed with muramyl dipeptides.

Authors:  C Jupin; M Parant; L Chedid; C Damais
Journal:  Inflammation       Date:  1987-06       Impact factor: 4.092

4.  Thymotaxin: a thymic epithelial peptide chemotactic for T-cell precursors.

Authors:  B A Imhof; M A Deugnier; J M Girault; S Champion; C Damais; T Itoh; J P Thiery
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Defective production of leucocytic endogenous mediator (interleukin 1) by peripheral blood leucocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease.

Authors:  J T Whicher; A M Gilbert; C Westacott; C Hutton; P A Dieppe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

6.  Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs.

Authors:  N E Byars
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

7.  Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.

Authors:  M Parant; L Chedid
Journal:  Infection       Date:  1985       Impact factor: 3.553

8.  Peptidoglycan fragments decrease food intake and body weight gain in rats.

Authors:  K J Biberstine; R S Rosenthal
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.

Authors:  M Parant; L Chedid
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

10.  Demonstration of interleukin 1 activity in apparently homogeneous specimens of the pI 5 form of rabbit endogenous pyrogen.

Authors:  D F Hanson; P A Murphy
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.